A heated clash over drug pricing is unfolding this week in Canada where Alexion Pharmaceuticals is challenging how the government attempts to control excessive prices.
The battle is actually the latest round in a long-running drama between the drug maker and the Patented Medicine Review Board, which successfully argued Alexion overcharged for Soliris, a medicine that is used to treat a pair of rare diseases. The drug costs either $380,000 or $585,000 in US dollars, depending upon the ailment being treated, and some provincial governments have declined coverage.
About the Author Reprints
